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The major drug binding site of sodium channels is inaccessible from the extracellular
side, drug molecules can only access it either from the membrane phase, or from
the intracellular aqueous phase. For this reason, ligand-membrane interactions are as
important determinants of inhibitor properties, as ligand-protein interactions. One-way
to probe this is to modify the pH of the extracellular fluid, which alters the ratio of
charged vs. uncharged forms of some compounds, thereby changing their interaction
with the membrane. In this electrophysiology study we used three different pH
values: 6.0, 7.3, and 8.6 to test the significance of the protonation-deprotonation
equilibrium in drug access and affinity. We investigated drugs of several different
indications: carbamazepine, lamotrigine, phenytoin, lidocaine, bupivacaine, mexiletine,
flecainide, ranolazine, riluzole, memantine, ritanserin, tolperisone, silperisone, ambroxol,
haloperidol, chlorpromazine, clozapine, fluoxetine, sertraline, paroxetine, amitriptyline,
imipramine, desipramine, maprotiline, nisoxetine, mianserin, mirtazapine, venlafaxine,
nefazodone, and trazodone. We recorded the pH-dependence of potency, reversibility,
as well as onset/offset kinetics. As expected, we observed a strong correlation between
the acidic dissociation constant (pKa) of drugs and the pH-dependence of their potency.
Unexpectedly, however, the pH-dependence of reversibility or kinetics showed diverse
patterns, not simple correlation. Our data are best explained by a model where drug
molecules can be trapped in at least two chemically different environments: A hydrophilic
trap (which may be the aqueous cavity within the inner vestibule), which favors polar and
less lipophilic compounds, and a lipophilic trap (whichmay be themembrane phase itself,
and/or lipophilic binding sites on the channel). Rescue from the hydrophilic and lipophilic
traps can be promoted by alkalic and acidic extracellular pH, respectively.
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Introduction
The pH dependence of local anesthetic action has been observed
almost a century ago, and the mechanism of pH dependence of
sodium channel inhibitor properties has been studied for more
than half a century (Ritchie and Greengard, 1966; Butterworth
and Strichartz, 1990). From the clinical point of view, potency,
distribution, and possible adverse effects of local anesthetics all
largely depend on pH of the local tissue and/or the plasma
(Lagan and McLure, 2004). From the theoretical point of
view, pH-dependence of the inhibition may provide substantial
insight into the mechanism of inhibition. Results of pH-
dependence experiments led to the proposal of two alternative
access pathways for local anesthetics to their binding site, a
hydrophobic pathway through the membrane phase, and a
hydrophilic pathway for the charged form of the molecules from
the intracellular side of the membrane, through the activation
gate of the channel. Both pathways require overcoming of a
hydrophobic barrier (Narahashi et al., 1970; Hille, 1977a,b),
which process is thought to require deprotonation. Because most
local anesthetic molecules have an acidic dissociation constant
(pKa) near physiological pH, the ratio of charged/protonated
and uncharged/deprotonated forms is much dependent on
pH. It has been observed that both onset and offset rates
are accelerated by alkalic pH (Chernoff and Strichartz, 1990;
Nettleton andWang, 1990), and that the effect of pH is due to the
deprotonation/protonation equilibrium of inhibitor drugs (Liu
et al., 2003).
It has only recently been discovered, that beyond classic
sodium channel inhibitor drugs, such as local anesthetics, type
I antiarrhythmics and anticonvulsants, many drugs of other
indications are also able to potently inhibit sodium channels
(Huang et al., 2006), in fact sodium channels are among the
most promiscuous targets (Lounkine et al., 2012). This presents
the question, whether the binding site, access routes, and
mechanisms proposed for pH-dependence originally described
for local anesthetics and antiarrhythmics are generally true for
all sodium channel inhibitors.
In this study we aimed to investigate a number of
sodium channel inhibitors, which are of different therapeutical
indications, and which have different chemical properties. We
intended to investigate the following questions:
- Which chemical properties determine the pH-dependence
of inhibition? Are there other important factors beyond
lipophilicity (Bokesch et al., 1986; Courtney and Strichartz,
1987; Ehring et al., 1988; Brown et al., 1997, 1999; Wang et al.,
2009; Desaphy et al., 2012), pKa (Courtney and Strichartz,
1987; Gerner et al., 2003; Liu et al., 2003), and size (Courtney,
1988, 1990)?
- Which specific processes might contribute to pH-dependence?
Is deprotonation indeed the most important, and rate-limiting
step?
- Which specific properties of inhibition are dependent
on pH? We measured apparent affinity, reversibility, and
onset/offset kinetics. Are these all equally affected by
pH?
These questions have been previously studied for several different
compounds, but a comparative study of a considerable number of
diverse compounds has not yet been performed. In this study we
compared the pH-dependence of inhibition by 30 different drugs,
using the exact same experimental protocol, which, together
with the analysis of their predicted chemical properties using
a cheminformatics software, allowed the identification of some
key chemical properties which determine pH-dependence of
inhibition.
Methods
Cell culture, electrophysiology and cheminformatics were carried
out as in our previous study (Lenkey et al., 2010), where some
aspects of the methodology are given in more details.
Cell Culture
HEK-293 cells stably expressing rNav1.2 sodium channels were
obtained from NeuroSearch (Ballerup, Denmark). The cells were
grown in Dulbecco’s modified Eagle medium supplemented with
10% FBS. Prior to use, the cells were trypsinized and subsequently
kept in suspension in the QPatch cell storage facility in CHO-S-
SFM-II medium.
Solutions
Composition of the extracellular solution was: (in mM): 140
NaCl, 3 KCl, 1 CaCl2 1 MgCl2, 0.1 CdCl2, 20 TEA-Cl, 5 HEPES,
adjusted to pH 7.3, Osmolality: 320 mOsm. The intracellular
solution consisted of the following (in mM): 135 CsF, 10
NaCl, 1 EGTA, 10 HEPES, adjusted to pH 7.3 with CsOH
(∼5mM), Osmolality: 320 mOsm. Drugs were synthesized in
Gedeon Richter Plc. (paroxetine, lamotrigine, tolperisone, and
silperisone), obtained from Tocris (mirtazapine, venlafaxine,
nefazodone, flecainide ritanserin, and ambroxol), or Sigma (the
rest of the compounds). Stock solutions were prepared at 10–
100mM in water, ethanol or DMSO, for the list of stock
solutions see (Lenkey et al., 2010). The full list of drugs,
with their three-letter codes, concentration, as well as their
main therapeutic indication and main mechanism of action are
shown in Table 1. In the case of two compounds, lidocaine and
memantine we tested different concentrations, in order to verify
our presumption that patterns of inhibition are due to the specific
chemical properties of individual compounds, and are largely
independent of concentration. The choice of concentrations used
in this study may seem unusually high. The reason for this is, that
in this study we did not aim to investigate close-to physiological
inhibition mechanisms, but focused on studying the properties
of access and egress pathways of the drugs instead. It is known
that the affinity of sodium channel inhibitors is conformational
state-dependent, and therefore it is also membrane potential-,
use-, and frequency-dependent (Nardi et al., 2012). In a meta-
analysis of 73 electrophysiology papers containing 246 individual
measurements of 139 distinct compounds we found that the
affinity to depolarized (open or inactivated) conformations was
on an average 31-fold higher than to resting conformation
(Lenkey et al., 2011). Because the 5Hz protocol does not contain
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TABLE 1 | Most important chemical properties calculated for the 30 compounds.
Colors indicate the class they were clustered into. Color scales on numerical data are shown to help comparison. AccC, hydrogen bond acceptor count; DonC, hydrogen bond donor
count; PSA, polar surface area; pKa, acidic dissociation constant; logN(pKa), logarithm of the percentage of the neutral form at pH = 7.3, calculated from pKa; AAC, aromatic atom
count; logP, logarithm of the partitioning coefficient (calculated for the neutral form); logD(*.*), logarithm of the distribution coefficient at the given pH; MPA, minimal projection area; VdW,
Van der Waals volume; MW, molecular weight.
prolonged- or high frequency depolarizations, it gives IC50 values
closer to resting affinity values. We chose concentrations (based
on pilot studies) so that, if possible, the inhibition would be
between 25 and 75% for all three pH values. We managed to
achieve this in the case of 14 of the 30 compounds; for 13
compounds the inhibition was within the 25–75% interval for
two out of the three pH values. From the remaining three
compounds, in the case of silperisone, the choice of concentration
was ideal, but the pH-dependence was too strong: 100µMcaused
23, 42, and 79% inhibition at pH 6.0, 7.3, and 8.6, respectively.
The inhibition by venlafaxine was unexpectedly weak using this
protocol, therefore even 100µM turned out to cause less than
25% inhibition at pH values 6.0 and 7.3. Finally, in the case
of flecainide, the unusually high concentration (300µM) was
necessary because of its unique mode of action: this drug can
access open channels only (Anno and Hondeghem, 1990; Liu
et al., 2002, 2003), therefore in this protocol it has a slow onset
kinetics, especially at acidic pH.
Electrophysiology
All electrophysiological experiments were conducted on Qpatch-
16 or QPatch HT instruments (Sophion, Ballerup, Denmark)
using QPlate™ chips (Kutchinsky et al., 2003; Korsgaard et al.,
2009; Danker and Möller, 2014). Data were sampled at a
frequency of 25 kHz and filtered at 5 kHz. Junction potential
was calculated to be −11mV and was corrected for. Histograms
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for the distribution of electrical properties of cells (membrane
resistance, series resistance, whole-cell capacitance, current
amplitude), as well as activation and steady state inactivation
curves are shown in the supplement of (Lenkey et al., 2010). Cells
having membrane resistance < 500 MOhm, series resistance >
9 MOhm, or capacitance > 22 pF were excluded from analysis.
The experimental protocol was also identical to the one used
in our previous study: sodium channels were activated by 5Hz
trains of 5 depolarizations (−90 to −10mV) repeated in every
20 s. In this study, however, the same control–drug-application–
washout sequence was repeated four times: at neutral, acidic,
alkalic, and again neutral pH. The peak amplitudes of sodium
currents throughout the whole experiment are shown plotted
against time in Figure 1 and Supplementary Figure 1.
Data Analysis and Statistics
Initial analysis, including subtraction of leak and capacitive
artifacts, as well as peak detection were done in the QPatch
software. For further analysis and statistics Microsoft Excel
(including Data Analysis Tools) and OriginPro 2015 (Originlab,
Northampton, MA) were used. All experiments were normalized
to the amplitude of the current evoked by the first depolarization
of the last train under control conditions. Each plot shows the
averaged normalized amplitudes of five individual experiments.
For all four drug applications in an experiment, apparent affinity,
onset and offset time constants as well as reversibility values
were calculated. Apparent affinities (Kapp) were calculated from
inhibition values as described in Lenkey et al. (2011), from the
simplified Hill equation: one-to-one binding (i.e., nH = 1) was
supposed, so the Hill equation is reduced to Inh= cc/(cc+Kapp),
from which Kapp was calculated. (This method is equivalent
to applying the Lineweaver-Burk plot method using a single
concentration.) Reversibility values were calculated from control
(c), inhibited (i), and wash-out (w) amplitudes as follows:
Reversibility = (w-i)/(c-i). Reversibility values should not be
regarded as experimental platform-independent properties of
compounds. Recovery recorded in automated patch clamp
systems, where solution flow is discontinuous (such as the
QPatch instrument) is typically substantially lower than in
manual patch clamp systems with continuous solution exchange
[e.g., compare (Lenkey et al., 2010) with (Lenkey et al., 2006)],
which is especially true for highly lipophilic “sticky” compounds
(Danker and Möller, 2014). However, reversibility values are
a valuable source of information regarding physicochemical
differences between individual drugs, or between effects of
the same drug under different extracellular pH conditions.
Onset and offset time constants were determined by single
exponential fitting to individual experiments. For neutral pH
numerical data were given as the average of the data from
the first and the last drug applications. Thin black lines on
Figure 1 and Supplemental Figure 1 show the average of five
fitted exponentials, (not the exponential fitted to the averaged
normalized amplitudes). The numerical values of apparent
affinity, onset and offset time constants and reversibility are
shown in Table 2, and their relative position is illustrated in
Figure 2. Affinity and time constant values were logarithmically
transformed for statistics, therefore we show their geometric
mean. For recovery data no transformation was done, and we
show arithmetic mean values. Significance values were calculated
using paired, two-tailed Student’s t-test based on five pairs of
apparent affinity (log transform), time constant (log transform),
or reversibility values obtained from five individual experiments.
Because of the large number of comparisons in this study,
we accepted p < 0.01 as significant. Cluster analysis was
done using Ward’s minimum variance method, with Euclidean
distance measure. Data were normalized by subtracting the mean
(after logarithmic transformation in the case of apparent affinity
and time constants), and dividing by the standard deviation.
In order to prevent changing the sign of differences, difference
values (pH = 6.0 vs. 7.3, 7.3, vs. 8.6 and 6.0 vs. 8.6) were
normalized by only dividing by the standard deviation. Data
for the cluster analysis included the three normalized apparent
affinity values (at acidic, neutral and alkalic pH), the three
normalized reversibility values, the three normalized onset time
constants (offset time constants were not included, because at low
recovery they were often ambiguous), and the difference values
for all of these, altogether 18 variables. We have experimented
with using different distance measures, replacing onset time
constants with the average of onset and offset time constants, and
assigning different weights (ranging between 1 and 2) to specific
variables we considered more important, but these approaches
did not radically change the overall classification, only the
position of a few compounds (as we describe below). In the
Results section, therefore, we will discuss the clusters obtained
using the unweighted data with Euclidean distance measure.
Cheminformatics
Chemical descriptors were generated using JChem for Excel 15.4
software from ChemAxon (Budapest, Hungary). Wherever the
new version calculated descriptors differently from the earlier
version (5.3.3) used in our previous studies (Lenkey et al.,
2010, 2011), we used the values of the earlier version to ensure
comparability. Based on the calculated descriptor values for the
30 drugs we created the correlation matrix for all descriptors in
order to detect redundancies. Then together with all normalized
properties of inhibition for the 30 drugs (which are: apparent
affinity, reversibility, and onset/offset time constants for all three
pH values, as well as the pairwise differences between pH values
for all these properties; altogether 24 properties) we created the
correlation matrix between chemical descriptors and properties
of inhibition. Based on these correlation matrices we chose
which of the descriptors are the most predictive and the least
redundant. Lipophilicity is one of the most important properties,
we expressed it using four different descriptors: the partition
coefficient (logP) expresses the logarithm of octanol/water
distribution of the compound’s neutral form, while distribution
coefficient (logD) considers all forms of the compound that
are present at a specific pH. We calculated logD for three
different pH values. The acidic dissociation constant had a
skewed distribution, therefore in some of the plots we calculated
from it the percentage of neutral molecules at pH = 7.3 using
the rearranged Henderson-Hasselbalch equation: N(pKa) =
100∗10pH/(10pH + 10pKa). The logarithm of N(pKa) gave a fairly
even distribution, and therefore it was used in several of the plots.
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FIGURE 1 | Examples for the different types of pH-dependence patterns exhibited by the compounds. Peak amplitudes are plotted against time during the
whole experiment. Sodium currents were evoked by 5Hz trains of 5 pulses, repeated in every 20 s. The pH of the perfusion medium was changed in the following
order: neutral (black-gray-black)—acidic (red-pink-red)—neutral (black)—alkalic (dark-light-dark blue)—neutral (black-gray-black). Each major period consisted of 10
(Continued)
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FIGURE 1 | Continued
control trains, 10 trains during drug application (shown by light colors) and 10 trains during wash-out. Each plot shows the averaged normalized amplitudes of five
individual experiments. All experiments were normalized to the amplitude of the current evoked by the first depolarization of the last train under control conditions. Thin
black lines show the average of the five exponentials fit to individual curves, as described in Methods. Example traces from individual measurements are shown in the
right panel. Black traces: Currents evoked by the first depolarization of the last control train [circled in (A)]. Gray traces: Currents evoked by the first depolarization of
the last train during the first drug application period [circled in (A)]. Scale bars: 1 nA, 1ms. (A–G) Examples for a member of each class from Class (A–G).
TABLE 2 | Properties of inhibition measured for 30 drugs at 3 pH values.
pH values are shown in the 2nd row. For two drugs, lidocaine and memantine, two different concentrations were used. Concentrations are shown in the 3rd column. Color scales on
numerical data are shown to help comparison. A more complete table including ratios and significance levels is given as Supplemental Table 1.
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FIGURE 2 | pH-dependence of three properties of inhibiton. The pH-dependence of (A) apparent affinity, (B) reversibility, and (C) onset time constant is
illustrated for the 30 drugs. For the sake of clarity, the plots are divided into three parts: Left column shows Class C (dark blue) and Class F (light blue) compounds.
Middle column shows Class A (red), Class B (light green), and Class E (purple) compounds. Right column shows Class D (dark green) and Class G (magenta)
compounds. Identity of compounds is shown by the three-letter code, as shown in Table 1, except: M30 – memantine 30µM, M100 – memantine 100µM, L300 –
lidocaine 300µM, L1000 – lidocaine 1000µM.
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Of the many descriptors that show the size of the molecule, we
found the geometrical descriptors “minimal projection area” the
most useful. This describes not the size but the “slimness” of the
molecule, which is an important property for a binding site that
can be accessed through a fenestration.
Results
General Observations
Based on the literature of the external pH-dependence of
sodium channel inhibitors, we expected to observe the following
tendencies:
(a) For predominantly positively charged molecules the affinity
was expected to be increased at alkalic pH (because
deprotonation can help overcoming the hydrophobic
barrier), while for predominantly neutral molecules no such
effect was expected.
(b) The onset and offset of inhibition was expected to be
accelerated at alkalic pH for predominantly positively
charged compounds.
(c) Recovery from inhibition was expected to be incomplete at
acidic pH, but accelerated by alkalic extracellular solution
(Schwarz et al., 1977; Chernoff and Strichartz, 1990).
As regards point “(a),” in most but not all cases we have observed
what was expected, while in the case of “(b)” and “(c),” we found
important, unexpected differences from these presumptions for
the majority of compounds. The pH-dependence of the extent
of inhibition indeed seemed to be determined by the acidic
dissociation constant (pKa) of individual compounds, i.e., by
what percentage of the compound is in its charged vs. neutral
form. However, as for the onset/offset rates, and the reversibility
of inhibition, the relationship was more complex, and not solely
determined by pKa. Most importantly, we found an obvious
heterogeneity even among predominantly charged compounds
(i.e., those with pKa values higher than 7.3), depending on
their additional chemical properties. We have identified several
distinct types of pH-dependence, and attempted to determine
which specific chemical properties cause individual compounds
to belong to a particular type. From the correlations between
chemical properties and types of pH-dependence, we gained
some insight into the details of the access pathway for inhibitor
molecules to the binding site.
Using qualitative categories (like increase, decrease, or no
change) we observed six distinct types of pH-dependence.
Cluster analysis confirmed our preliminary classification, but
quite dependably classified compounds into seven, not six
categories. We will first introduce these seven major types of
pH-dependence. Next, we will discuss their respective chemical
properties. Obviously, these seven categories are artificial,
because most chemical properties change along a continuum.
We introduce them because this helps to discuss differences in
a coherent way, and to understand major effects of chemical
properties on properties of inhibition. It is necessary, however,
to investigate these correlations irrespectively of subjective
classification. This analysis will be presented in the last section.
The most important calculated chemical properties for all
30 compounds are shown in Table 1. One typical example of
each major type of pH-dependence is illustrated in Figure 1. In
Supplemental Figure 1. we show plots of peak amplitudes for all
compounds.
Major Types of pH-dependent Inhibition
The three anticonvulsant compounds, carbamazepine,
phenytoin, and lamotrigine behaved similarly, and it was
obvious from the observation of the data that they formed a
separate group, which we named “Class A.” Since this group
contained predominantly neutral molecules, their potency was
not expected to be enhanced by alkalic pH. Furthermore, their
onset/offset rate was expected to be fast, because deprotonation
should not limit drug access to- and egress from the binding
site, and the inhibition was expected to be reversible. Indeed, the
extent of inhibition in this group was essentially independent
of the pH, the onset/offset kinetics was fast, and reversibility
was practically full at all three pH values (Table 2, red lines
in Figure 2). To succinctly characterize Class A, it contains
“pH-independent-affinity—fast-onset—reversible” compounds.
Further characteristics of this group were the relatively low
affinity (high apparent affinity values). The effect of 300µM
carbamazepine, a representative of Class A is shown in
Figure 1A. The apparent affinity of lamotrigine was in fact
not totally pH-independent, but showed an “inverse” pH-
dependence, being most potent at acidic pH. When considering
all its properties, however, it obviously belonged to this class.
We investigated which other compounds might belong here
by performing cluster analysis, and found that three additional
compounds, trazodone, ranolazine, and lidocaine were sorted
into Class A. It was evident that acidic dissociation constant
(pKa) was the single most important factor which determined
whether or not a compound belonged to Class A. From the eight
compounds with the lowest pKa values, six was clustered here,
with the exception of riluzole and nefazodone. Both riluzole
and nefazodone had higher affinity than the group’s average,
which probably was the main reason why cluster analysis placed
them into other groups. It was surprising that lidocaine too
was clustered with the anticonvulsants and not with other
antiarrhythmics, even though its apparent affinity did have a
moderate (1.78- and 2.46-fold for 300 and 1000µM lidocaine,
respectively), but significant (p < 0.01) pH-dependence.
However, lidocaine has the lowest pKa (7.75; i.e., 26% is neutral
at pH = 7.3) among the investigated antiarrhythmics, and it
had the fastest kinetics, highest recovery and lowest affinity.
All these properties make its inhibition pattern similar to those
of the three anticonvulsants. In our previous study, where we
recorded other properties of inhibition, lidocaine had also been
found to be closer to these anticonvulsants than flecainide or
bupivacaine [see Figure 2 of (Lenkey et al., 2010)]. However,
we must emphasize that the protocol we used in this study
investigates only one aspect of the inhibition mechanism, and
therefore similar inhibition patterns in this test do not prove
similar mode of action. Amplitude plots showing the effect of
phenytoin, lamotrigine, trazodone, ranolazine, and lidocaine are
shown in Supplemental Figure 1.
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Only the two antiarrhythmic compounds flecainide
(Supplemental Figure 1) and bupivacaine (Figure 1B) behaved
exactly as expected from the literature: The pH dependence of
inhibition was not only reflected in apparent affinities and in
reversibility, but also in the kinetics of inhibition. A definite
acceleration of both onset and offset was evident at alkalic pH.
This group was therefore named “pH dependent affinity—pH
dependent kinetics—pH dependent reversibility” group; Class B
(light green lines in Figure 2). No other compound clustered
together with these two antiarrhythmics. Although the pH-
dependence of mexiletine was qualitatively similar, in terms of
reversibility and kinetics it was weaker, with significance levels
p = 0.06 and p = 0.03, respectively (Supplemental Table 1).
Tricyclic (amitriptyline—Figure 1C, imipramine and
desipramine), and selective serotonin reuptake inhibitor
(fluoxetine, sertraline, and paroxetine) antidepressants formed
a separate “pH dependent affinity—slow kinetics—strongly
pH dependent recovery” class (Class C). Amplitude plots are
shown in Supplemental Figure 1, the properties of this group,
as compared to others are illustrated in Figure 2 (dark blue
lines). The most obvious sign of belonging to this class was
the extreme pH-dependence of recovery; while at pH = 6.0
it ranged between 0.57 and 0.74, at pH = 8.6 it was less
than 0.14 for all six compounds. The onset time constant
at pH = 7.3 was in the range of 15–59 s. In the case of
desipramine and paroxetine, but not the rest of the compounds,
a significant acceleration of onset was also observed at higher
pH. (Quantitative properties are given in Table 2, and illustrated
in Figure 2).
Two antidepressant compounds, venlafaxine (Figure 1D)
and mirtazapine (Supplemental Figure 1; dark green lines in
Figure 2) were exceptional because their reversibility was almost
complete at pH = 7.3, but their effect was virtually irreversible
at pH = 6.0. Decreased reversibility at pH = 6.0 was not
at all uncommon among compounds of all classes, but only
for these two compounds was the difference significant at
p < 0.01 level. Their group, Class D, can be characterized
as “pH dependent affinity—fast kinetics—low acidic recovery”
group.
The inhibition pattern shown by the anxiolytic ritanserin
(Figure 1E, purple line in Figure 2) was totally different from the
inhibition caused by all the rest of the drugs we have studied,
with the possible exception of nefazodone. First, ritanserin was
the only drug that was most potent at neutral pH (3.5-fold
more potent than at pH = 6.0 (p < 0.01), and 5.9-fold more
potent than at pH = 8.6 (p < 0.01); although nefazodone
showed similar tendency, the differences were nonsignificant—
see Supplemental Table 1). Second, in spite of being the most
potent at neutral pH, it was also the most reversible at this pH
(p < 0.001 between pH = 7.3 and 8.6); for nefazodone the
differences were significant at p = 0.023, and 0.062 when pH
= 7.3 was compared to pH = 6.0 and 8.6, respectively. Third,
ritanserin showed the largest, and most significant deceleration
of both the onset and the offset at alkalic pH (nefazodone showed
only a slight, non-significant tendency). Cluster analysis, which
is based on quantitative data in most trials did not classify the
two drugs into the same group, therefore ritanserin remains
the only member of Class E, which is characterized as the
group of “most potent at neutral pH—decelerated by alkalic
pH—low alkalic recovery” compounds. Although nefazodone was
in most trials clustered into Class G, (see below) we think it
appropriate to call attention to the qualitative similarity of its
inhibition pattern to that of ritanserin. Note that ritanserin
was the most lipophilic of the 30 drugs (logD (7.3) = 4.45,
logP = 5.31—in fact it was the only “non-drug-like” compound
according to Lipinski’s rule of five), and also the one with
the highest molecular weight (MW = 478 g), furthermore it
had the second highest minimal projection area (66.9 Å2),
and the highest aromatic atom count (AAC = 21). Chemical
properties of nefazodone were similar: it was the molecule with
the highest minimum projection area (75.1 Å2) and distribution
coefficient [logD (7.3) = 4.40], as well as the second highest
molecular weight (MW = 470 g) and aromatic atom count
(17). These large, strongly lipophilic molecules seemed to have
behaved differently under these experimental conditions, and
even might have had different binding site(s) than the rest of the
drugs.
The two remaining classes contained compounds of moderate
reversibility (0.29–0.68), and moderate pH-dependence of both
apparent affinity and reversibility (light blue lines in Figure 2).
Class F contained “pH-dependent affinity—intermediate
kinetics—alkalization dependent recovery” compounds, these
drugs had apparent affinity ratios (pH = 7.3 vs. 8.6) between
2.51 and 5.38, and their reversibility was also strongly sensitive
to alkalization. The compounds sorted into this class were
haloperidol nisoxetine, clozapine, mexiletine, memantine,
silperisone, and tolperisone (Supplemental Figure 1).
Class G compounds showed only weak pH-dependence of
affinity, with pH = 7.3 vs. 8.6 ratios being between 0.6 and 2.09.
This group of compounds could be characterized as “moderately
pH-dependent affinity—intermediate kinetics—moderately pH-
dependent reversibility.” It is a rather heterogeneous group,
containing some compounds (e.g., riluzole, nefazodone) that
have been shown to act by clearly different mechanisms of
action using other experimental protocols (Lenkey et al.,
2010, and unpublished data). Nevertheless, they are all similar
in their moderate pH-dependence. Ambroxol (Figure 1G),
maprotiline, mianserin, chlorpromazine, riluzole, and
nefazodone (Supplemental Figure 1) were sorted into this
class.
Results of cluster analysis, of course, are not to be considered
indisputable; therefore we performed multiple analyses as
described in theMethods section. Most analyses created the same
clusters, but for three of the compounds the classification was
uncertain. Haloperidol was sorted into Class C in some of the
analyses, probably because of its high affinity and slow kinetics.
Tolperisone had very fast kinetics, and it showed highest recovery
at neutral pH, which properties caused it to be closer to Class A.
However, considering the definite pH-dependence of its affinity,
we are confident that it rather belongs to Class F. Finally, the
weak pH-dependence of apparent affinity placed mianserin into
Class G, but because of its strongly pH-dependent reversibility, it
was occasionally sorted into Class F. The main properties of the
classes are summarized in Table 3.
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TABLE 3 | Qualitative properties of pH-dependence classes.
KD app Reversibility τonset
Acidic Alkalic Acidic Alkalic Acidic Alkalic
Class A








Class G ↑ ↓
NFZ↑ MIA↓
Summary of the observed qualitative differences between different classes of pH-
dependence. The effect of acidic (pH = 6.0) and alkalic (pH = 8.6) medium is shown
on three properties of inhibition: apparent dissociation constant (KD app), reversibility and
onset time constant. Bold arrows ( ) indicate substantial modification, thin arrows (↑↓)
indicate weak modification, sign indicates no significant effect. Note that increased
apparent dissociation constant ( ) indicates decreased apparent affinity and vice versa.
Similarly, increased onset time constant ( ) indicates decelerated onset and vice versa.
Occurrence of exceptions is indicated at the bottom of the cells. Distinguishing features
are in red fonts.
Chemical Properties of Classes
We have detected different types of pH-dependent inhibition
patterns. The question is, if we can explain why different
classes behave differently, and if we can predict the pH-
dependent behavior of specific compounds from chemical
structure.
We address these questions in two consecutive steps. First we
show that key chemical properties indeed seem to determine the
type of pH-dependence. We illustrate the position of the classes
introduced above in the chemical space. For this to perform, it
is necessary to simplify the n-dimensional chemical space, and
to find the most informative chemical properties. The selection
of these will be described in the next section, in which we will
use a different approach: we will investigate the correlations
between specific quantifiable properties of inhibition and specific
chemical properties, while we disregard the classification of the
compounds. This is necessary if we intend to use all available
information, including within-class differences.
The areas inhabited by the classes in three projections of
the n-dimensional chemical space are illustrated in Figure 3.
In Figure 3A we plotted logD(6.0) values against logN(pKa).
Considering the areas occupied by different classes (see inset),
we can conclude that predominantly neutral compounds with
high logD(6.0) are more likely to manifest Class A or Class E
type pH-dependence. Class C and Class F type pH-dependence
occurred with predominantly charged compounds, with lower
logD(6.0) values. Class B, Class D, and Class G mechanisms were
not determined by logN(pKa) or logD(6.0, because compounds
belonging to these classes were scattered widely. We need,
therefore, to try to find descriptors which can differentiate Class
A from Class E, as well as Class C from Class F; and which are
able to define Classes B, D, and G.
FIGURE 3 | Position of compound classes within the chemical space.
We attempted to correlate pH-dependent behavior patterns (i.e., Classes A–G)
with the chemical properties of the classes (i.e., their location within the
chemical space). Classes are color-coded (same colors as in Figure 2),
three-letter codes identify individual drugs. The insets are the exact same
plots, where we marked the outlines of the areas occupied by specific classes.
(A) logD(6.3) vs. logN(pKa) plot, (B) logP vs. aromatic atom count (AAC) plot,
and (C) polar surface area (PSA) (Å2) vs. minimal projection area (Å2).
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Figure 3B illustrates logP values plotted against aromatic
atom count (AAC) values. Both chemical properties are
extremely important in determining the type of inhibition in
general (Lenkey et al., 2010, 2011) and of pH-dependence in
particular. We can observe that Classes A and E are completely
differentiated: Class A contains compounds with relatively low
logP (<3.2), and with one or two aromatic rings. Three aromatic
rings, and high logP (>4.5), on the other hand, seems to
predestine compounds to manifest Class E characteristics (i.e.,
alkalic pH hinders recovery and decelerates binding/unbinding
kinetics). Indeed, aromatic atom count has been found to be
a major determinant of reversibility (Lenkey et al., 2010), and
of unbinding rate (Smith et al., 2006). The difference between
Classes C and F also seems to be established: Class C compounds
(i.e., the ones with very low reversibility at alkalic pH) tended
to be more lipophilic compounds with two aromatic rings,
while Class F compounds were either less lipophilic, or had
only one (none for memantine) aromatic rings. A small overlap
nevertheless existed between the two groups, which is not
surprising, since as we mentioned, haloperidol was occasionally
clustered into Class A. More unexpected was the fact that three
Class G compounds covered the exact same area as Class C
compounds. The two Class B compounds both have one aromatic
ring, and they are very close in terms of logP as well, but of
course two compounds are too few to reliably define an area in
the chemical space. The descriptors logP and AAC still could not
help much to localize Class D and Class G compounds within the
chemical space.
In Figure 3C, polar surface area was plotted against minimal
projection area (the “slimness” of the molecule). This plot
gives a hint regarding the requirements for Class B properties:
both compounds had minimal projection areas between 60
and 70 Å2. Class E compounds were the bulkiest, and Class
C compounds were still relatively wide. High polar surface
area seemed to predetermine compounds to have Class A
or B properties, while low polar surface area favored Class
C, F, and G mechanisms. We still have not understood
what makes a compound act with Class D properties (i.e.,
having very low reversibility at acidic pH); unexpectedly it
was apparently not strictly determined by pKa, since these
values differed considerably for the two compounds (mirtazapine
– 7.8, venlafaxine – 8.9). Note, however, that this range is
exactly between the range of Class A and Class C compounds.
They both had relatively low logP values (3.2 and 2.7),
and moderate polar surface areas (20.6 and 33.9 Å2), these
properties, however do not differentiate them from other classes.
Class G is obviously a heterogeneous group of compounds,
which have been clustered together because they exhibited no
obvious distinguishing features in their pH-dependent inhibition
pattern. Heterogeneity of the group, and the low number
of compounds prevented proper characterization in terms of
chemical properties. Apart from ambroxol and riluzole, which
are different from the rest of the class in all important chemical
properties, the three Class G compounds which were close to
Class C properties in terms of AAC and logP (Figure 3B), and
also shared their range along minimal projection area and PSA
axes.
We can finally summarize what can be predicted regarding
pH-dependent inhibition properties, based on the chemical
properties of compounds.
When a large fraction of the molecules is neutral at pH = 7.3
(i.e., pKa < 7.8), they are not very lipophilic (logP < 3.2), and
considerably polar (PSA > 33), there is good chance that we will
find Class A inhibition, i.e., fast and reversible inhibition which is
not much affected by pH.
When moderately low pKa (7.0–8.0) was accompanied with
high lipophilicity (logD > 4.6) and aromaticity (more than
two aromatic rings), a different pattern emerged. Class E
compounds, ritanserin and nefazodone were the only ones
where the potency actually decreased at alkalic pH. Onset
rates were also decelerated. We reason that while for most
compounds alkalization helps to overcome the energy barrier
needed for deprotonation, for these highly lipophilic and
aromatic compounds the equilibrium is probably shifted toward
the membrane-bound neutral form already at pH = 7.3. Further
alkalization makes molecules even more reluctant to leave the
membrane phase, and therefore at alkalic pH fewer molecules
actually enter the internal cavity within the channel, and access
the binding site.
Having moderate pKa values also allowed two special
inhibition patterns.When it was combined with low lipophilicity,
Class D pattern emerged; which essentially means low acidic
reversibility. We speculate, that acidification could effectively
keep molecules charged within the inner cavity of the channel,
thereby preventing their re-enrty to the membrane phase. It is
logical that this effect cannot work with molecules that are highly
lipophilic, or with molecules that are predominantly neutral
even at pH = 6.0. The two compounds that exhibited Class
D inhibition had logP values in the same range as Class A
compounds, but higher pKa values (not as high though as that
of Class C compounds). Nevertheless, from our data Class D
properties cannot be unambiguously predicted. Note that some
Class A compounds, as well as tolperisone, bupivacaine and
ambroxol, also showed compromised recovery at acidic pH,
therefore it seemed advisable to investigate correlations without
considering which class individual drugs belong to (see next
section).
Moderate pKa values also allowed Class B properties (i.e.,
when alkalization increased potency and also accelerated onset
kinetics), when compounds had higher lipophilicity than Class A
compounds (logP > 3), were rather bulky (minimum projection
area around 60–70 Å2), and contained only one aromatic ring.
Class B type of inhibition, nevertheless, was not a “moderate pKa-
specific” phenomenon, since the pKa value of flecainide was 9.61.
We would suppose that having a single aromatic ring and a high
minimum projection area (it was only exceeded by the two Class
E compounds; Figure 3C), are more important determinants
of Class B pattern. Moderate pKa value with high lipophilicity
(bupivacaine), and high pKa value with moderate lipophilicity
(flecainide) both seem to allow Class B properties.
When high pKa (> 9) is combined with high lipophilicity
(logP > 4), typical Class C properties are expected to occur (low
alkalic reversibility, and strong pH-dependence of both apparent
affinity and reversibility). There were two atypical Class C
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compounds as well, desipramine and paroxetine, which showed
acceleration of onset kinetics upon alkalization, similarly to
Class B compounds. These two compounds had the lowest logP
and logD values within their class (Table 1, Figures 3A,B), in
which they were similar to flecainide. Their minimum projection
area and polar surface area values were also close to those of
Class B compounds (Figure 3C). However, when we consider
their reversibility at alkalic pH, their difference from Class B is
unquestionable, and their affiliation with Class C seems justified.
We suppose that the chemical basis of this must be the presence
of two aromatic rings.
High pKa and high lipophilicity did not guarantee Class C
properties, but also allowed Class F and Class G inhibition
patterns. Even if we consider compounds with two aromatic
rings, which have pKa > 9 and logP > 3.1, we still have
four additional compounds besides the six Class C compounds
included in this group: nisoxetine and clozapine from Class F, as
well as maprotiline and chlorpromazine fromClass G. Nisoxetine
and clozapine show inhibition patterns that are indeed very
similar to Class C compounds (only their reversibility at alkalic
pH is higher), while maprotiline and chlorpromazine had a
somewhat different pattern: they had very low reversibility at
all three pH values. This indicates that the mentioned chemical
properties may allow different patterns of pH-dependence,
depending on some additional, not yet identified chemical
properties.
The difference between Class C (practically irreversible at
alkalic pH) and Class F (moderately reversible) compounds
seemed to be that lower logP value or only one aromatic ring
seemed to predispose compounds to Class F inhibition pattern.
Finally Class G seemed to be a collection of chemically diverse
molecules, which happened to have no obviously distinguishable
characteristics in this specific experimental protocol. Although
nefazodone was in most trials clustered into this group, we felt
it reasonable to discuss it as a member of Class E, because
it showed qualitative features identical to ritanserin. Mianserin
also had some resemblance to Class E both chemically [see its
logD(6.0) and logN(pKa)], and in inhibition properties (slowing
of onset rate with increased pH). Riluzole and ambroxol also have
been shown to differ in their modes of action from the rest of
Class G compounds (Lenkey et al., 2010). The rest of Class G;
maprotiline, and chlorpromazine are somewhat similar to Class
F compounds both chemically and in inhibition properties, but
their reversibility is less pH-dependent.We expect that here again
more can be learned from investigation of correlations in an
approach that is blind to classification.
The Chemical Basis of Different Aspects of
pH-dependent Inhibition
We will discuss six major phenomena that could be quantified
from the amplitude plots. We attempted to synthesize the
observations, and place them into a framework of a general
hypothesis regarding the major steps along the access pathway
of drugs toward the binding site. All assumed sub-processes of
drug access and egress, which may be of different importance
depending on the chemical nature of individual compounds are
summarized in Figure 4. Our major findings are summarized
FIGURE 4 | Schematic model of the sub-processes of drug access. An
illustration of the hypothetical sub-processes of drug access that must be
supposed based on experimental data: (1) partitioning of the charged
molecule at the outer membrane interface; (2) protonation/deprotonation in
the extracellular space; (3) partitioning of the neutral molecule at the outer
membrane interface; (4) protonation/deprotonation at the outer membrane
interface; (5) entry/exit through the fenestration (hydrophobic pathway); (6)
protonation/deprotonation within the inner vestibule; (7) protonation/
deprotonation at the inner membrane interface; (8) intracellular diffusion; (9)
entry/exit through the activation gate (hydrophilic pathway).
in Figure 5, which: (in the 2nd column) shows a characteristic
occurrence of each observed phenomenon chosen from Figure 1
(or Supplemental Figure 1); lists the major chemical properties
which seem to determine their occurrence (3rd column); and
shows a graphic representation of their hypothetical explanation
(4th column).
pH-dependent Apparent Affinity
For all predominantly positively charged molecules the affinity
was increased at alkalic pH, as it was expected. When the
apparent affinity ratios [IC50 (pH = 6.0)/IC50 (pH = 8.6)]
were plotted against pKa values, an abrupt increase was seen at
about pKa = 8 (Figure 6A). Seven compounds out of the 30
had pKa values below 7.7, and none of them was significantly
more potent at pH = 8.6 (the maximal difference was 1.43-
fold). On the other hand, all compounds with pKa value above
8.2 (18 out of the 30) had apparent affinity ratios above 2
(range: 2.17–12.48). The affinity ratio - pKa correlation was
evidently not linear, therefore, we also plotted the affinity ratios
against the logarithm of the percentage of neutral form at pH =
7.3 (logN(pKa); calculated using the Henderson-Hasselbalch
equation as described in Methods). This plot gave a significant
correlation (R2 = 0.49; p < 0.001). The correlation coefficient
was even higher (R2 = 0.61; p < 0.001) when the logarithm
of the apparent affinity ratios was plotted against logN(pKa)
(Figure 6B). These results suggest that the apparent affinity
is manifestly determined by the ability of drug molecules to
populate an intramembranous pool, which is only accessible for
their neutral form (Figure 5, 1st row).
Accelerated/decelerated Onset Kinetics
Onset and offset kinetics seemed to change in parallel, but
because the offset rate was often occluded by incomplete
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FIGURE 5 | Suggested contribution of the sub-processes of drug access to seven experimentally detected phenomena. Seven phenomena of
pH-dependence detected in experiments. 2nd column: Illustration of the phenomena on peak amplitude vs. time plots. 3rd column: Chemical properties that are likely
to determine occurrence of the phenomenon. 4th column: Sub-processes affected during the occurrence of the phenomena. Green and red arrows indicate
accelerated and decelerated sub-processes, respectively. Circled molecules indicate accumulation of drug molecules in that specific position.
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FIGURE 6 | Chemical properties affecting pH-dependent affinity and onset kinetics. Correlations of the extent of pH-dependence with chemical properties.
Classes are color-coded (same colors as in Figure 2), three-letter codes identify individual drugs. (A) Ratios of apparent affinities measured at alkalic vs. neutral
solution, plotted against calculated pKa values of the drugs. (B) The same correlation could be made close to linear by mathematical transformations: The logarithm of
the alkalic/neutral apparent affinity ratio, plotted against the logarithm of the percentage of neutral form at pH = 7.3 [logN(pKa)] (neutral fraction was calculated from
pKa values using the Henderson–Hasselbalch equation—see Methods). (C) pH-dependent acceleration/deceleration of onset as a function of aromatic atom count
(AAC). (D) pH-dependent acceleration/deceleration of onset as a function of logD(7.3).
recovery, it seemed best to concentrate on onset time constants
for quantitative evaluation. It was remarkable that the expected
significant acceleration of both onset and offset was only
observed in the case of two drugs: flecainide and bupivacaine
at p < 0.01 level. Three additional compounds (mexiletine,
paroxetine, and desipramine) showed acceleration of onset at
p < 0.05 level, but no significant change of offset. For
six rapidly acting drugs (carbamazepine, lidocaine, riluzole,
ambroxol, silperisone, tolperisone) the acceleration of onset
might have gone undetected, because our experimental protocol
might not have resolved it. For the rest of the compounds,
however, the onset/offset rates were resolvable, but still no
acceleration was observed. Three of the compounds, ritanserin
(p < 0.001), trazodone (p < 0.01), and mianserin (p < 0.05),
even exhibited decelerated onset at alkalic pH. This suggests that
the lipophilic (membrane) environment may not only present an
energy barrier to overcome, but also an energetically favorable
trap along the access route. Searching for chemical properties
that could predict the pH-dependence of onset rates, we found
the highest correlation with aromaticity (aromatic atom count
or aromatic ring count), and with logD values (at pH = 7.3 or
8.6) (Figures 6C,D). There is a significant correlation between
aromaticity and logD [e.g., R2 = 0.52; p < 0.001 between
aromatic atom count and logD(7.3)], therefore one cannot be
sure which of these two correlations represents a genuine causal
relationship. It can be observed, nevertheless, that acceleration
of the onset of inhibition due to alkalic pH was only seen for
compounds with two or less aromatic rings, and logD(7.3) lower
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than 2.5, while for compounds with two or more aromatic rings,
and logD(7.3) higher than 2.6 the onset tended to slow down.
In the case of the former group, the dominant effect must have
been the accelerated crossing of the lipophilic barrier due to
deprotonation (Figure 5, 2nd row), while for the latter (more
aromatic, more lipophilic) group, the deceleration was probably
due to being trapped in a lipophilic environment (Figure 5, 3rd
row). For the compounds where the effect of pH was evident
on their apparent affinity, but not on the onset and offset
kinetics, we suppose that these two opposing effects may have
counterbalanced each other.
Decreased Recovery at Acidic pH
Decreased recovery at acidic pH was not at all general
even among the predominantly positively charged molecules.
Only two compounds: venlafaxine and mirtazapine showed
significantly (p < 0.01) decreased recovery at pH = 6.0,
while the differences for nefazodone (p = 0.024), ambroxol
(p = 0.036), lidocaine (p = 0.046), tolperisone (p =
0.057), and carbamazepine (p = 0.075) were non-significant
at p < 0.01 level. The tendency was more frequent with
drugs which are relatively hydrophilic (logP < ∼3), and which
have a substantial neutral fraction at pH = 7.3 (pKa <
9; N(pKa) > 1%; Figures 7A,B). We can also observe that
(the predominantly charged) Class C compounds showed an
opposite effect; acidic pH helped recovery from the inhibition
by these drugs. In order to see the combined effects of
lipophilicity and charged-neutral ratio, we plotted logP values
against logN(pKa) (Figure 7C). Color code shows the ratio
of acidic/neutral recovery values: light and dark red indicates
moderately and strongly decreased recovery, respectively; gray
indicates no change; light and dark blue indicates moderately
and strongly increased recovery, respectively. The size of the
data points indicates the level of significance. It seems that the
compounds that are prone to be trapped at pH = 6.0 are more
hydrophilic, and/or have a substantial neutral fraction at pH
= 7.3 which becomes protonated at acidic pH (Figure 5, 4th
row). Some of the “decreased-acidic-recovery” compounds, such
as riluzole, lamotrigine, and carbamazepine, however, cannot
be protonated even at pH = 6.0. All three compounds have,
however, an exceptionally high number of hydrogen bond
acceptors and donors, as well as polar surface compared to their
size (Figure 7D). This suggests that the effect of external pH
may go beyond changing the charged/neutral ratio of ligands,
and may also affect protein-ligand interaction by other ways,
possibly via interfering with hydrogen bonds or van der Waals
forces. This chemical environment, which seems to be able to trap
hydrophilic, polar or charged molecules must be different from
the lipophilic trap mentioned above, we suggest that it is located
within the inner vestibule of the channel.
Until now we have discussed the compounds that had a
lower recovery at acidic pH than at neutral pH. A somewhat
different, but equally reasonable question would be to ask which
compounds had low recovery at acidic pH, irrespectively of
their reversibility at neutral pH. From Figure 2B and Table 2
we can see that some compounds have low reversibility at all
three pH values. There are five compounds with reversibility
below 0.6 at all three pH values: sertraline, ritanserin, nefazodone,
maprotiline, and chlorpromazine. The most obvious property of
this group is that they all have very high logP values. In terms
of pKa they are rather heterogeneous, although they all have a
substantial charged fraction at pH = 7.3, and are predominantly
charged at pH = 6.0. We will return to discussing this group in
section “Alkalization-induced Recovery.”
Decreased Recovery at Alkalic pH
Decreased recovery at alkalic pH, was much more common,
especially for more lipophilic drugs with relatively high pKa
(Figure 7E). Essentially all compounds which are predominantly
charged at neutral pH (pKa > 7.3), and are highly lipophilic
(logP > 3) exhibited decreased recovery at pH = 8.6 at an
at least p < 0.05 significance level. The difference was 1.49-
to 5.07-fold as compared to pH = 7.3; see the three shades
of blue in Figure 7E. (In the case of the only exception,
tolperisone, the difference was 1.35-fold, with p = 0.05.) The
reason why maprotiline and chlorpromazine were exceptions is,
that these compounds already had very low recovery even at
pH = 7.3 (Supplemental Figure 1). For predominantly neutral
compounds it is expected that alkalic pH would not change their
reversibility (red points: no significant change, or less than 1.4-
fold change). Interestingly, it seems that it was not enough to
neutralize a substantial fraction of the molecules by alkalic pH, in
order to show low reversibility they also needed to be lipophilic.
This must have been the reason while memantine, mexiletine,
ambroxol, and venlafaxine failed to exhibit strongly decreased
recovery at pH = 8.6. This indicates that the environment where
molecules are trapped at alkalic pHmust be apolar and lipophilic.
We reason that high lipophilicity and high pKa (i.e., being
predominantly positively charged) counteract each other, the
former helps the accumulation of compounds in this lipophilic
environment, from which access to the binding site is easy,
while the latter retains molecules in the outer, charged layer of
the membrane, from where the binding site is not accessible.
In such situation this sensitive balance can be easily shifted by
alkalization of the extracellular fluid, when more molecules are
allowed into the lipophilic environment; or by acidification, when
more molecules are retained (Figure 5, 5th row).
Acidification-induced Recovery
Observing the plots of peak amplitudes
(Supplemental Figure 1), we can note that the incidents of
external pH change may also be of interest. Although in these
points no inhibitor was given or washed out, when channels
had not recovered fully from prior drug effects, we often saw
unmistakable signs of enhanced recovery produced by pH change
alone. We had four such points of pH change in our solution
exchange protocol: neutral-to-acidic, acidic-to-neutral, neutral-
to-alkalic, and alkalic-to-neutral transitions. We observed
enhanced recovery for specific subsets of the compounds at all
four transitions. Interestingly, some of the drugs reacted with
enhanced recovery to both acidification and alkalization.
Acidification-induced recovery: In the absence of inhibitor,
exchange from neutral (pH = 7.3) to acidic (pH = 6.0) solution
caused an instantaneous drop of the amplitude to 72.4± 1.6% of
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FIGURE 7 | Chemical properties affecting pH-dependent reversibility. Correlations of acidification- and alkalization-induced changes in recovery with chemical
properties. (A) Ratios of acidic (pH = 6.0) vs. neutral (pH = 7.3) recovery are plotted against logP and (B) against pKa. In both panels classes are color-coded (as in
Figure 2), three-letter codes identify individual drugs. (C) Acidic/neutral recovery ratios are color coded, and plotted on the logP against logN(pKa) plane, and (D) on
the logP against polar surface area/molecular weight (PSA/MW) plane. Light and dark red indicates moderately and strongly decreased recovery, respectively; gray
indicates no change; light and dark blue indicates moderately and strongly increased recovery, respectively. [See (D) for color codes. “R” stands for “ratio”). The size of
the data points indicates the level of significance, as it is also shown in (D). (E) Neutral/alkalic recovery ratios are color coded and plotted on the logP against
logN(pKa) plane. Light to dark blue indicates increasing ratios, red indicates minimal or no change. Levels of significance are coded by the size of data points. Codes
are shown in the lower left corner.
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the control value. The effect of acidic pH on sodium currents is
a well-known phenomenon, thought to be due to channel block
by protons (Woodhull, 1973). Upon acidic-to-neutral exchange
the inhibition instantaneously and fully recovered. No significant
change in the amplitude was observed at neutral to alkalic or
alkalic to neutral transitions.
When an inhibitor had previously been perfused at neutral
pH, and the recovery was not complete (mostly Class C, F, and
G compounds), neutral-to-acidic solution exchange evoked a
component of recovery. We quantified this by calculating the
ratio of current amplitudes evoked at the end of this section
vs. the amplitude of the first current evoked in acidic solution
(circled in the inset shown in the 6th row of Figure 5). The
explanation is essentially the same as in the case of “decreased
recovery at alkalic pH” (see above), except that in this case the
recovery must be compromised even at neutral pH. Lowering
the pH then helps the protonation of the compounds, which
shifts the “protonated-in-the-outer-membrane-layer-pool” vs.
“deprotonated-within-the-membrane-pool” equilibrium, and
also increases aqueous solubility, helping partitioning into the
aqueous phase, and therefore wash-out is accelerated. Most,
but not all compounds, which showed enhanced recovery upon
neutral-to-acidic exchange reacted similarly to alkalic-to-neutral
exchange (both are shown by red arrows in the 6th row of
Figure 5); there was a significant correlation (p < 0.001)
between the reactions of compounds to these two pH decreasing
steps (Figure 8A; Supplemental Figure 1). Decreasing the pH
must have helped escape from the lipophilic trap, therefore
this phenomenon would be most evident for predominantly
charged, lipophilic compounds. Indeed, logP had a significant
correlation (p < 0.01) with the extent of acidification-induced
recovery (Figure 8B), and there was a definite optimum of pKa
for it between 8.8 and 10.4 (Figure 8C). In these Figures 8B,C
acidification-induced recovery was calculated by the sum of
the logarithms of the two recovery steps. We can conclude that
as we have expected, essentially the same chemical properties
predispose compounds both to “decreased recovery at alkalic
pH” and to “acidification induced recovery.”
Alkalization-induced Recovery
Alkalization-induced-recovery could in principle be monitored
at incidents of acidic-to-neutral (gray arrow in 7th row of
Figure 5), and neutral-to-alkalic (red arrow in 7th row of
Figure 5) transitions. Calculating from the former, however, is
impracticable, because acidic-to-neutral transition reflects the
combination of three effects. For example for all Group A
compounds but sertraline the amplitude becomes larger upon re-
application of neutral medium after acidic medium perfusion.
This may be due to alkalization-induced recovery occurring
upon acidic-to-neutral transition, but also to acidification-
induced recovery, which have occurred at the beginning of
perfusion by acidic medium. In addition, removal of proton
block also occurs concurrently. For this reason, it is difficult
to judge the true extent of increase due to alkalization-induced
recovery alone. There is no such complication at the neutral-to-
alkalic transition, which, we believe, truly reflects the effect of
alkalization.
FIGURE 8 | Chemical properties affecting acidification-induced
recovery. (A) Correlation between recovery caused by alkalic-to-neutral and
neutral-to-acidic solution exchange. (B) Acidification-induced recovery plotted
against logP and (C) pKa. The sum of the logarithms of the two recovery steps
(neutral-to-acidic and alkalic-to-neutral) was used as a measure of
acidification-induced recovery.
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If “acidification-induced-recovery” was essentially equivalent
with “decreased alkalic recovery,” then one could expect
that “alkalization-induced-recovery” should be equivalent with
“decreased acidic recovery,” and therefore we should best see
alkalization-induced-recovery with compounds that are prone to
accumulate in the hydrophilic trap, i.e., relatively hydrophilic,
polar drugs with a relatively low pKa. This, however, was
absolutely not what we found. In fact the compounds that
showed “decreased acidic recovery” (either a tendency or
a significant difference) failed to display at the same time
“alkalization-induced recovery” (with the only exception of
nefazodone). These typically small, polar, relatively hydrophilic
compounds, with a substantial neutral fraction at pH = 7.3,
were fully released by neutralization, and alkalization did
not further help their escape. The compounds that needed
alkalization to be released, were to be found in the “low
acidic recovery” group, these compounds had low reversibility
at both acidic and neutral pH, and therefore, perfusion of
neutral medium could not release them fully. As we have
mentioned, they were chemically different from the “decreased
acidic recovery” group, most of them being highly lipophilic
(Figure 9). Of the compounds with the 7 highest logP values,
5 showed prominent alkalization-induced recovery (sertraline,
nefazodone, ritanserin, maprotiline, and chlorpromazine). These
are the exact same compounds, which had low reversibility
values (< 0.6) under all three pH conditions. In the case
of nisoxetine (logP = 3.14) the phenomenon was small and
only significant at p = 0.05 level. We suppose that for this
group of compounds both lipophilic and hydrophilic interactions
contributed to binding. The finding that high lipophilicity was
a requirement for both acidification and alkalization-induced
recovery suggests that the same lipophilic drug may exhibit
FIGURE 9 | Chemical properties affecting alkalization-induced
recovery. Neutral-to-alkalic solution exchange-induced recovery plotted
against logP.
both phenomena. Indeed, all six compounds showed enhanced
recovery both upon neutral-to-alkalic and alkalic-to-neutral
transitions (Supplemental Figure 1).
The fact that both alkalization and acidification can help
the recovery of some compounds suggests that accumulation of
drug molecules can occur simultaneously in at least two distinct
pools, which represent different chemical environments. It is
possible that for full recovery, drug molecules need to take two
consecutive steps, one requiring deprotonation (this might be
the step of entering the membrane phase from the binding site;
i.e., steps #6 and #5 in Figure 4) and the other protonation (this
might be regaining the charge, and/or partitioning to the aqueous
phase; i.e., steps #2, #4 and #1 in Figure 4). The rate-limiting step
may be either, or both. It is also possible that alternative binding
sites co-exist for protonated and for neutral forms of compounds.
We assume that the high incidence of non-monotonic pH-
dependence of the recovery (Figure 2B), and the occasional
occurrence of non-monotonicity even in the apparent affinity
plots (Figure 2A) may also be due to this “double accumulation”
phenomenon.
Discussion
Of the three major propositions from the literature of pH-
dependent action of sodium channel inhibitors, we have
confirmed and refined one, and re-specified two:
First, our data confirmed that the extent of pH-dependence
of potency is dependent on the ratio of charged/neutral forms of
the molecules, and that in general alkalization increases potency
of partially charged compounds. However, we have noticed that
extremely high lipophilicity and aromaticity may override this
tendency: For such compounds we hypothesize that alkalization
may prevent their entry into the aqueous environment of the
inner cavity, thereby decreasing their potency. In addition,
the relatively weak pH-dependence of lidocaine was somewhat
surprising; this points to the importance of the pKa value
of compounds. We propose that the calculated pKa value
of drugs (such as local anesthetics) may be used to predict
how much its effect will be resistant to acidification of the
tissue, and that it is advisable to use compounds with low
enough pKa in situations where tissue acidification may be a
problem.
Next, we observed that the onset kinetics was not always
accelerated by alkalization. The major predictors of the pH-
dependence of kinetics were pKa, lipophilicity and aromaticity.
Onset kinetics of predominantly positively charged compounds
(with a high pKa) would be accelerated by alkalization, because
deprotonation helps these molecules enter the membrane phase.
However, highly aromatic and lipophilic compounds may find
the membrane phase an energetically favorable environment,
which may slow down their access to the binding site. The
two effects may counterbalance each other, acceleration is
dominant with less lipophilic compounds, and deceleration is
dominant for lipophilic compounds (especially if they also highly
aromatic) with relatively low pKa, i.e., which do not depend
on alkalization for effective partitioning into the membrane
phase.
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Finally, although acidification hindered recovery for some
of the drugs, it was much more common that recovery was
hindered by alkalization. The former phenomenon was common
among relatively hydrophilic and polar compounds with low pKa
value, while the latter was a characteristic of highly lipophilic,
predominantly charged compounds.
The complex effect of pH on onset/offset kinetics and recovery
suggest the existence of at least two chemically different pools
where drug molecules can be accumulated. Drugs (especially the
ones that have a substantial neutral fraction at pH = 7.3) can be
trapped by protonation, probably in a polar environment (which
could be the aqueous cavity within the channel itself), and can
be rescued by alkalization. Drugs that are strongly lipophilic,
and are predominantly charged at neutral pH can be trapped
after deprotonation in an apolar environment (which may be the
membrane, or an apolar sub-region at the channel-membrane
interface), and can be rescued by acidification. Finally, some of
the most lipophilic drugs show low reversibility at both acidic
and alkalic pH, and both alkalization and acidification may help
the rescue of a fraction of the molecules. The supposed major
steps of drug access and egress are illustrated in Figure 4. When
the external pH is changed, many of the sub-processes can be
affected, depending on the chemical nature of the drug molecule.
The scheme we propose can account for all diverse phenomena
observed in the experiments, as it is specified in the schematic
figures of the right column of Figure 5.
The conclusion of our study shows the importance of the
membrane phase in the apparent affinity and the onset/offset
kinetics of sodium channel inhibitors. It is a common mistake
to attribute slow onset and recovery of inhibition to the slow
inactivated state preference of the inhibitor (Karoly et al.,
2010), when it is equally possible that the rate of onset
and offset is limited by drug-membrane interactions. The
complexity of ligand-membrane interactions as shown by this
study suggests that these interactions may be as important as
ligand-protein interactions in determining the mode of action
of sodium channel inhibitors, and ultimately their therapeutic
applicability. Therapeutic profiles of individual drugs are in
general determined by their target spectrum, and within a target
class, their subtype selectivity. This is somewhat different in
the case of sodium channel isoforms, where the key residues
involved in drug binding are conserved across all mammalian
isoforms, therefore, their binding region is practically identical
(Mike and Lukacs, 2010; Nardi et al., 2012). Indeed, most of
the efforts during the last two decades to develop truly isoform-
selective compounds (i.e., with more than 10-fold selectivity)
have failed so far, only Nav1.8 selective compounds have been
successfully developed (Clare, 2006; Lenkey et al., 2011; Nardi
et al., 2012). For other isoforms, the minimal inter-subtype
selectivity is overshadowed by the huge state-selectivity of
typical sodium channel inhibitors: affinities between different
conformational states may differ by several orders of magnitude
(Lenkey et al., 2010, 2011). Therefore, the essence of the
therapeutic applicability of sodium channel inhibitors is thought
to be “functional selectivity,” not subtype selectivity. Functional
selectivity is the direct consequence of the mode of action,
therefore investigation of specific modes of action is a key to
successful drug development strategies (Nardi et al., 2012).
The complexity and heterogeneity of drug-membrane
interactions points to two interesting aspects of sodium channel
inhibitor action. One is the question of alternative binding sites,
the other is the role of membrane composition in the potency of
sodium channel inhibitors.
It is quite possible that compounds with so widely different
chemical properties may have different binding sites on the
channel. The fact that extracellular pH had a profound
effect even on highly lipophilic compounds, indicates that
for these compounds the most favorable position is probably
at the membrane interface. Accumulation of compounds at
this position has already been shown in molecular dynamics
simulations for isoflurane, benzocaine, and phenytoin (Raju et al.,
2013; Martin et al., 2014), which are polar but not charged
compounds. Having charged compounds accumulated in this
position may modify channel function indirectly by modifying
membrane structure and electric charge density, and directly by
interacting with the voltage-sensor. Similar mechanisms have
been shown for lipid modulation of ion channels (e.g., Hite et al.,
2014; Zaydman and Cui, 2014). It is possible, therefore, that
inhibitor molecules may modulate sodium channel gating even
without entering the inner vestibule. Earlier we have proposed
the presence of alternative binding sites (Mike and Lukacs,
2010), based on the wide chemical variety of inhibitor molecules,
and on the exceptional pharmacological promiscuity of sodium
channels (Huang et al., 2006; Lounkine et al., 2012; Zhang
et al., 2015). Molecular dynamics studies indeed confirmed the
presence of multiple energetically favorable positions for sodium
channel inhibitor compounds (Raju et al., 2013; Barber et al.,
2014; Boiteux et al., 2014; Martin and Corry, 2014) within the
channel. It is also possible, however, that compounds which are
highly lipophilic and at the same time have a high pKa (i.e.,
not easily deprotonated), and therefore probably accumulate
at the membrane interface near the channel, may modulate
channel gating via an interaction with the voltage sensor
domains.
The second aspect is, that if this position is indeed
energetically favorable, than the composition of the membrane
is a major determinant of the potency of these drugs. There
is plenty of evidence for the importance of ligand-membrane
interactions in determining drug potency for transmembrane
proteins (see Box1 in Morris et al., 2012). It is therefore
conceivable that specific sodium channel inhibitor drugs show
preference for pathological membrane composition, as it has
been proposed (Morris et al., 2012), or even show selectivity
among cell types or subcellular compartments depending on
their membrane composition. These ideas suggest that a
deeper understanding of ligand-membrane interactions may
lead to development of therapeutically more specific inhibitor
molecules.
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